Aramis Biosciences Completes Enrollment of its Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced the completion of enrollment in its Phase II...

Aramis Biosciences Announces First Patient Dosed in Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease BOSTON, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced that the first patient has been dosed in its...

Aramis Biosciences Announces FDA Clearance of IND Application for A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Disease BOSTON, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...

Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology Founded by Renowned Experts in Ophthalmology and Immunology Launches with $10.5 million Series A Financing Led by Safar Partners to Advance Disease-Modifying Therapy for Ocular Surface Disease into...